Introduction
Carrotosis is a group of diseases caused by a fungus of aroma, which can be drained to multiple parts of the lungs, noses, eyes and central nervous system, with varying degrees of severity, ranging from mild allergies to fatal invasive infections. In the health-care system, primary health-care facilities are entrusted with important primary and basic medical care, which is essential for the rational use of medicines and the accurate treatment of the disease, not only for the patient ‘ s prognosis, but also for the effective use of medical resources and the quality of overall medical care.
II. Status of treatment of crony disease in primary health-care institutions
(i) Limited diagnostic capacity
At present, primary health-care institutions face many challenges in the diagnosis of the disease. Microbiological screening is relatively uniform, and traditional fungi culture, although an important basis for diagnosis, is slow to grow, with a long training cycle, and generally takes 2-7 days or more to obtain positive results, making early diagnosis difficult and easily delayed. In addition, the lack of advanced molecular biological diagnostic techniques at the grass-roots level, such as the PCR (polycol chain reaction) for the detection of curvature nucleic acid, the inability to quickly and accurately identify the fungus and to detect its resistant genes, has led to lower sensitivity and specificity in the diagnosis and to difficulties in meeting the need for precision treatment.
(ii) Irregular drug supply and use
In the area of drug treatment, although anti-fluent drugs, such as Vulcanium and Icracontium, are common drugs for the treatment of carcinoma, there is a shortage of drugs in primary health-care facilities. Some of the new anti-facter drugs are not available in a timely manner owing to high prices and limited procurement channels, limiting the choice of treatment options. Moreover, there is an irregular use of drugs by primary health-care personnel. There is a lack of sufficient experience and knowledge on dose adjustments, treatment management and adverse-response monitoring of drugs. For example, while individual blood concentrations in Vulcanium vary significantly, requiring individualized dosage adjustments based on the patient ‘ s condition and state of health, it is often difficult for primary doctors to achieve precision in the use of the drug, which affects the efficacy of the treatment and may even lead to adverse reactions due to an inappropriate dose, increasing the pain and the risk of treatment.
III. Strategies for the rational use of drug precision treatment
(i) Strengthening diagnostic technology
Primary health-care institutions should gradually introduce rapid, simple and accurate diagnostic techniques. For example, a quagic antigen test, such as the semi-emulsifiable glycerine (GM) test, which is of high sensitivity and specificity and allows for early warning of ailments and facilitates the timely initiation of treatment. At the same time, cooperation with higher-level hospitals or third-party testing institutions is being strengthened to conduct molecular biology tests through the delivery of specimens, to compensate for technical deficiencies, to achieve precision diagnosis and to provide a strong basis for rational use of medicines.
(ii) Regulating drug treatment processes
(b) Develop guidelines and guidelines for the treatment of carcinogens in primary health-care institutions, with a view to identifying the adaptation certificates, taboos, dose ranges, treatment programmes and elements for monitoring adverse effects. Training of primary health-care personnel on pharmacological characteristics and principles of clinical application of fungi-resistant drugs is strengthened. The establishment of multidisciplinary teams involving clinical pharmacists, who assist doctors in the development of individualized drug programmes, taking into account the specific circumstances of the patients, such as liver and kidney functions, and the combination of medications, as well as in the overall monitoring and evaluation of the drug treatment process, and the timely adjustment of drug dosages and treatment programmes to ensure safe and effective drug use.
(iii) Establishment of a two-way referral mechanism
In view of the technical and resource bottlenecks that may exist in primary health-care institutions in the treatment of severe aroma infections, a two-way referral mechanism should be established that is smooth with the higher-level hospital. Medical treatment and follow-up for patients with relatively minor conditions, clearly diagnosed and capable of treatment at the grass-roots level, under the guidance of specialists in the higher-level hospital, are regulated by a medical doctor at the primary level; further examination and treatment of patients with complex, undiagnosed or ineffective conditions are referred to the higher-level hospital in a timely manner, pending stabilization of the condition before being referred back to the primary-level health-care facility for the management of the period of rehabilitation, with a reasonable distribution of medical resources and the overall management of the patient.
Concluding remarks
Despite the difficulties faced by primary health-care institutions with regard to the rational use of drugs and the precision of the treatment of the disease, measures such as the strengthening of diagnostic techniques, the regulation of the treatment process and the establishment of a well-established two-way referral mechanism have made it possible to increase the level of treatment, to provide more timely, effective and accurate medical care to patients, to play an important role in ensuring the health of the population at the grass-roots level and in combating the infection of the disease, and to promote a high-quality, normative approach to primary health care.
